Natural oestrogen as an effective treatment for type-II hyperlipoproteinaemia in postmenopausal women.
Seventeen postmenopausal women with raised serum total and low-density-lipoprotein (L.D.L.) cholesterol concentrations were treated with oestradiol valerinate for 6 months. Serum-L.D.L.-cholesterol decreased in sixteen patients--the average change at 6 months was -18%. Serum-high-density-lipoprotein (H.D.L.) cholesterol increased by 30% during treatment and the mean H.D.L./L.D.L. cholesterol molar ratio rose significantly from 0.21 to 0.34. There was a significant positive correlation between the size of the decrease in L.D.L. cholesterol and initial L.D.L.-cholesterol concentration. Serum triglyceride and very-low-density-lipoprotein (V.L.D.L.) concentrations were not significantly changed by the treatment. The results suggest that type II hypercholesterolaemia may be taken as another indication for oestrogen therapy in postmenopausal women.
D000284:Administration, Oral; D000328:Adult; D002784:Cholesterol / Q000097:blood*; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006728:Hormones / Q000008:administration & dosage*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000037:antagonists & inhibitors / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D006728:Hormones; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D004958:Estradiol; D002784:Cholesterol